mln9708

Plasmacytoma

Mayo ClinicPhase 2Dormant

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 41/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Plasmacytoma cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Memorial Sloan Kettering Cancer Center	Phase 2	B
Cediranib M.D. Anderson Cancer Center	Phase 2	B
cc-5013 Memorial Sloan Kettering Cancer Center	Phase 2	B
FILGRASTIM M.D. Anderson Cancer Center	Phase 2	B
Busulphan M.D. Anderson Cancer Center	Phase 2	B

View all 19 →

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant

BB

Indicative ·

66 / 100

AmyloidosisDormant

BB

Indicative ·

64 / 100

Higher-risk Myelodysplastic SyndromeDormant

B

Indicative ·

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.